Recipient-Reported Reactogenicity of Different SARS-CoV-2 Vaccination Regimens Among Healthcare Professionals and Police Staff in Germany

Overview

Journal Vaccines (Basel)

Date 2023 Jul 29

PMID 37514963

Authors

Katharina Rau

Edgar von Heeringen

Nina Buhler

Stefan Wagenpfeil

Soren L Becker

Sophie Schneitler

Affiliations

Soon will be listed here.

Abstract

The rapid availability of effective vaccines against SARS-CoV-2 was key during the COVID-19 pandemic. However, vaccine hesitancy and relatively low vaccine coverage rates among the general population and particularly vulnerable populations such as healthcare staff reduced the potential benefits of these vaccines. During the early phase of the pandemic, fear of vaccine-related adverse events was common among individuals who refused vaccination. Between March and May 2021, we comparatively assessed the self-reported reactogenicity of different SARS-CoV-2 prime-boost regimens using mRNA-based (BNT162b2 and mRNA-1273) and vector-based vaccines (ChAdOx1 nCoV-19) in (a) healthcare workers (HCW), and (b) police staff from southwest Germany. The majority of participants (71.8%; 1564/2176) received a homologous vaccination. Among HCW, 75.0% were female, whereas 70.0% of police staff were male. The most frequently reported reactions following the first vaccine administration were pain at the injection site (77.94%; 1696/2176), tiredness (51.75%; 1126/2176), and headache (40.44%; 880/2176), which were more commonly reported by HCW as compared to police staff. In homologous, mRNA-based and heterologous vaccination schedules, more reactions were reported after the second vaccine dose. We conclude that the frequency and intensity of self-perceived vaccine reactogenicity may differ between specific population groups and might be mitigated by tailored communication strategies.

Citing Articles

Factors influencing adverse events following COVID-19 vaccination.

Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, Dos Santos G Hum Vaccin Immunother. 2024; 20(1):2323853.

PMID: 38445666 PMC: 10936640. DOI: 10.1080/21645515.2024.2323853.

References

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

Shah S, Chawla R . Cancer in corona times. Saudi J Anaesth. 2021; 14(4):504-509. PMC: 7796732. DOI: 10.4103/sja.SJA_317_20. View

Ho T, Chen Y, Chan H, Chang C, Chuang K, Lee C . The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2. Vaccines (Basel). 2021; 9(10). PMC: 8537265. DOI: 10.3390/vaccines9101163. View

Langer R, Thanner M . Pharmacists' attitudes toward influenza vaccination: does the COVID-19 pandemic make a difference?. Explor Res Clin Soc Pharm. 2023; 9:100235. PMC: 9925413. DOI: 10.1016/j.rcsop.2023.100235. View

Hajure M, Tariku M, Bekele F, Abdu Z, Dule A, Mohammedhussein M . Attitude Towards COVID-19 Vaccination Among Healthcare Workers: A Systematic Review. Infect Drug Resist. 2021; 14:3883-3897. PMC: 8464326. DOI: 10.2147/IDR.S332792. View

Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N . COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. J Med Virol. 2021; 94(4):1294-1299. PMC: 8661746. DOI: 10.1002/jmv.27463. View

Beattie A, Palmer K, Rees E, Riddell Z, Roberts C, Jordan R . Factors Affecting the Acceptance of Pandemic Influenza A H1N1 Vaccine amongst Essential Service Providers: A Cross Sectional Study. Vaccines (Basel). 2015; 1(1):17-33. PMC: 4552200. DOI: 10.3390/vaccines1010017. View

10.

Anderson E, Rouphael N, Widge A, Jackson L, Roberts P, Makhene M . Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; 383(25):2427-2438. PMC: 7556339. DOI: 10.1056/NEJMoa2028436. View

11.

Chenchula S, Karunakaran P, Sharma S, Chavan M . Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol. 2022; 94(7):2969-2976. PMC: 9088621. DOI: 10.1002/jmv.27697. View

12.

Abukhalil A, Shatat S, Abushehadeh R, Al-Shami N, Naseef H, Rabba A . Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infect Dis. 2023; 23(1):5. PMC: 9814351. DOI: 10.1186/s12879-022-07974-3. View

13.

Caban-Martinez A, Gaglani M, Olsho L, Grant L, Schaefer-Solle N, Thompson M . COVID-19 Vaccination Perspectives and Illnesses Among Law Enforcement Officers, Firefighters, and Other First Responders in the US, January to September 2021. JAMA Netw Open. 2022; 5(7):e2222640. PMC: 9297116. DOI: 10.1001/jamanetworkopen.2022.22640. View

14.

Mukherjee A, Wanjari U, Murali R, Chaudhary U, Renu K, Madhyastha H . Omicron variant infection and the associated immunological scenario. Immunobiology. 2022; 227(3):152222. PMC: 9065598. DOI: 10.1016/j.imbio.2022.152222. View

15.

Sun Y, Lin W, Dong W, Xu J . Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant. J Biosaf Biosecur. 2022; 4(1):33-37. PMC: 8718870. DOI: 10.1016/j.jobb.2021.12.001. View

16.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

17.

Mohammed R, Yazbik R, Baajajah L, Alharthy S, Alsalahi H, Mahjaa M . Side Effects Associated With Homologous and Heterologous COVID-19 Vaccines: A Cross-Sectional Study in Saudi Arabia. Cureus. 2023; 15(1):e34030. PMC: 9940124. DOI: 10.7759/cureus.34030. View

18.

The Lancet . Global governance for COVID-19 vaccines. Lancet. 2020; 395(10241):1883. PMC: 7302798. DOI: 10.1016/S0140-6736(20)31405-7. View

19.

Ibrahim A, Hamayoun M, Farid M, Al-Umra U, Shube M, Sumaili K . COVID-19 Vaccine Acceptance and Hesitancy in Health Care Workers in Somalia: Findings from a Fragile Country with No Previous Experience of Mass Adult Immunization. Vaccines (Basel). 2023; 11(4). PMC: 10144151. DOI: 10.3390/vaccines11040858. View

20.

Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View